The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Nanotechnology-Based Approach in Tuberculosis Treatment
Open accessAbstract
Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which still remains a major challenge for pharmaceutical technology. Nanoparticle-based ideology has shown convincing treatment and promising outcomes for chronic infectious diseases. Different types of nanocarriers have been evaluated as promising drug delivery systems for various administration routes. Controlled and sustained release of drugs is one of the advantages of nanoparticle-based antituberculosis drugs over free drug. It also reduces the dosage frequency and resolves the difficulty of low poor compliance. This paper reviews various nanotechnology-based therapies which can be used for the treatment of TB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis
Zahoor, A., Sharma, S., & Khuller, G. K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.07.012 · Cited by 314
Oral solid lipid nanoparticle-based antitubercular chemotherapy
Pandey, R., Sharma, S., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2005.08.009 · Cited by 271
The lectin–cell interaction and its implications to intestinal lectin-mediated drug delivery
Gabor, F., Bogner, E., Weissenboeck, A., & Wirth, M. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.015 · Cited by 247
Lectin-mediated mucosal delivery of drugs and microparticles
Clark, M. A., Hirst, B. H., & Jepson, M. A. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00070-3 · Cited by 236
Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.07.001 · Cited by 220
Deol, P., Khuller, G. K., & Joshi, K. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1211 · Cited by 128
Alginate-based sustained release drug delivery systems for tuberculosis
Ahmad, Z., & Khuller, G. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802600662 · Cited by 63
Cited by
Recent updates on drug resistance in Mycobacterium tuberculosis
Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 337
Biodegradable polymers and constructs: A novel approach in drug delivery
Prajapati, S. K., Jain, A., Jain, A., & Jain, S. (2019) · European Polymer Journal · doi:10.1016/j.eurpolymj.2019.08.018 · Cited by 308
Metadata
- Authors
- Nasiruddin, M., Neyaz, M. K., & Das, S.
- Venue
- Tuberculosis Research and Treatment
- Publisher
- Wiley
- Published
- 2017
- Volume
- 2017
- Pages
- 1-12
- ISSN
- 2090-150X (ISSN-L)
- 2090-1518
- OpenAlex
- W2580524684
- Cited by
- 177
- References
- 9
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanotechnology-Based Approach in Tuberculosis Treatment. https://app.cochat.ai/papers/10.1155/2017/4920209
- The paper
- Nasiruddin, M., Neyaz, M. K., & Das, S. (2017). Nanotechnology-Based Approach in Tuberculosis Treatment. Tuberculosis Research and Treatment. https://doi.org/10.1155/2017/4920209
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.